An interventional study of Berberine Hydrochloride in Colorectal Adenomas and Colorectal Cancers, sponsored by Jing-yuan Fang, MD, Ph. D. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Jing-yuan Fang, MD, Ph. D · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Berberine hydrochloride is a conventional component in Chinese medicine. In recent years, anticancer activity of berberine hydrochloride have been explored. The aim of this study is to investigate the effect of berberine hydrochloride on the human gut microbiome.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
This study's planned enrollment of 20 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Jing-yuan Fang, MD, Ph. D is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Outpatients undergoing colonoscopy at Renji Hospital who meet the following criteria:
Healthy subjects who meet the following criteria:
Exclusion Criteria:
The following outpatients undergoing colonoscopy at Renji Hospital:
The following healthy subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Berberine Hydrochloride
Oral Administration of Berberine Hydrochloride
Relative abundance of Akkermansia in fecal samples as measured by quantitative PCR (qPCR)
Fecal samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. The relative abundance of Akkermansia will be quantified using quantitative PCR (qPCR) targeting species-specific 16S rRNA gene sequences. Results will be expressed as the relative abundance normalized to total bacterial load (ΔCt method). Changes from baseline to post-treatment will be calculated for each participant and summarized across the study population.
Time frame: 2 weeks
Relative abundance and diversity of gut microbiota in fecal samples as assessed by 16S rRNA gene sequencing
Fecal samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. Gut microbiota composition will be analyzed using 16S rRNA gene sequencing. Outcomes will include: 1. relative abundance of bacterial taxa at the phylum and genus levels (excluding Akkermansia where applicable), and 2. alpha diversity indices (Shannon index). Changes from baseline to post-treatment will be calculated for each participant and summarized across the study population.
Time frame: 2 weeks
Plasma concentration of indole-3-pyruvic acid (IPyA) as measured before and after berberine hydrochloride administration
Peripheral blood samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. The concentration of indole-3-pyruvic acid (IPyA) in plasma will be quantified using a validated analytical method (liquid chromatography-mass spectrometry, LC-MS). Changes in IPyA concentration from baseline to post-administration will be calculated for each participant and summarized across the study population.
Time frame: 2 weeks
Fecal concentration of indole-3-pyruvic acid (IPyA) as measured before and after berberine hydrochloride administration
Fecal samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. The concentration of indole-3-pyruvic acid (IPyA) in fecal samples will be quantified using a validated analytical method (liquid chromatography-mass spectrometry, LC-MS). Changes in IPyA concentration from baseline to post-administration will be calculated for each participant and summarized across the study population.
Time frame: 2 weeks
Number of participants with abnormal liver and renal function laboratory values
Blood samples will be collected at baseline (prior to berberine hydrochloride administration) and after treatment. Liver function will be assessed by serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), and albumin. Renal function will be evaluated using serum creatinine (Cr) and blood urea nitrogen (BUN). Abnormal laboratory values will be defined according to institutional reference ranges. The number and proportion of participants with abnormal values after treatment will be reported. Changes from baseline for each parameter will also be summarized descriptively.
Time frame: 2 weeks
Proportion of VEGFA-positive cells in adenoma tissue as assessed by immunohistochemistry
Adenoma tissue samples will be obtained at the time of endoscopic resection for patients with colorectal adenomas, before and after administration of hydrochloride berberine. Immunohistochemical staining will be performed to detect vascular endothelial growth factor A (VEGFA) expression. The proportion of VEGFA-positive cells will be quantified by calculating the percentage of positively stained cells among total cells in representative high-power fields. Results will be summarized descriptively across participants. If applicable, comparisons with baseline or between subgroups may be explored.
Time frame: Baseline and at follow-up colonoscopy (approximately 6 months [±2 months] after treatment)
No study locations are listed for this record.
Start is estimated for May 2026; primary completion for Sep 2026, 4 months later.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 4 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berberine hydrochloride
Jing-yuan Fang, MD, Ph. D